Objective: Cellular metabolism is a key regulator of CD4 + Foxp3 + regulatory T cell (Treg) homeostasis, but the foundational studies in this area use free fatty acid treatment as a proxy for plasma triglycerides. In vivo, plasma triglyceride is the main source of fatty acids for cells, not free fatty acids. Design/Results: Using apolipoprotein C-III transgenic and LDLr -/mice, we report that the loss of lipoprotein triglycerides transport in these models results in protection from DSS-colitis and accumulation of intestinal Tregs and plasma IL-10. Total loss of apoC-III increases colitis severity. Tregs exposed to apoC-III increase lipolysis and fatty acid oxidation and apoC-III inhibits Bodipytriglyceride uptake. Therapeutic treatment of WT mice with apoC-III-containing lipoproteins protects mice from colitis. Conclusion: Our data suggest that therapies that reduce apoC-III could have negative effects in patients who are at risk of IBD, and conversely, that apoC-III could be a new therapeutic target to stimulate intestinal Tregs and IL-10 for the management of IBD. These data identify apoC-III and lipoprotein metabolism as a novel regulator of tolerance in the intestine.
Introduction
In vivo, fatty acids are delivered to cells in the form of triacylglycerol (TAG) in chylomicrons and very-low density lipoproteins (VLDL). These lipoproteins are synthesized in the intestine and liver, respectively, and carry TAG from dietary sources or from liver stores. Cells are able to utilize We demonstrate here that apoC-III transgenic (apoC-III Tg ) mice accumulate intestinal Tregs and IL-10 and are protected from DSS-induced colitis. Overexpression of apoC-III shifts Treg metabolism towards lipolysis and FAO. We show that triglyceride-rich lipoproteins can deliver fatty acids to Jurkat T cells, and this is inhibited by apoC-III. We also show that LDLr -/mice are protected from dextran sodium sulfate (DSS)-induced colitis and accumulate intestinal tolerogenic Tregs, and finally that IP injection of apoC-III-containing lipoproteins can protect WT mice from colitis. Our data suggest a new model: the inhibition of TAG delivery from lipoproteins to immune cells has profound effects on the accumulation of Tregs in the intestine and can protect mice from colitis in several different models. Our data suggest that therapies that reduce apoC-III, or LDLr, could have negative effects in patients who are at risk of IBD, and conversely, that apoC-III could improve IBD through a stimulation of intestinal Tregs and IL-10. These data identify apoC-III and lipoprotein metabolism as a novel regulator of tolerance in the intestine and as a potential new therapeutic target to stimulate intestinal Tregs and IL-10 for the management of IBD.
Results

Complete loss of APOC3 increases colitis severity and overexpression of APOC3 protects against colitis.
Due to its role in raising plasma triglycerides and increasing CVD risk, apoC-III is a target for pharmaceutical inhibition. In IBD patients APOC3 expression in the ileum is significantly reduced. We examined the effects of the total loss of APOC3 in apoC-III -/mice. We used the DSS model of colitis to determine whether apoC-III -/mice would be protected from colitis. DSS-induced colitis is a well-characterized model of IBD and involves multiple immune responses including Tregs, effector T cells, TNF-α, and IFN-γ [23] . We exposed WT and apoC-III -/mice to 4% DSS for 5 days followed by 5 days of water. We assessed the severity of colitis by qualitatively assessing disease progression with the macroscopic damage score. Body weight loss and colon lengths were comparable between WT and apoC-III -/mice after DSS treatment ( Figure 1, A and B ). However, apoC-III -/mice had significantly more-severe macroscopic damage with disease scores of 6.818 ± 0.5849 versus 4.364 ± 0.8008 in WT mice (*P=0.0224), as well as significantly increased spleen weight ( Figure 1 , C and D). ApoC-III -/mice and their WT counterparts had similar expression of TNF-a and IL-6 in the colon ( Figure 1E ). Colonic lamina propria (LP) and mesenteric lymph node (mLN)-resident Treg populations were similar between WT and apoC-III -/mice after DSS treatment (Figure 1 , F and G). ApoC-III -/mice had significantly greater CD14 + monocyte infiltration in the mLN compared to WT mice (*P=0.0432) ( Figure 1H ). Monocyte infiltration into the gut-associated lymphoid tissue can aggravate colonic inflammation [24] . Therefore, the loss of apoC-III in mice is accompanied by an increase severity of DSS-colitis, which aligns with the findings in humans that APOC3 expression is lowered in IBD.
We next asked whether overexpression of APOC3 would protect mice from colitis. We used our colony of apoC-III Tg mice, which overexpress human APOC3, driven by the human APOC3 promoter at ~five-fold the level of endogenous mouse APOC3 in liver, duodenum, and ileum. These mice maintain normal tissue-specific distribution and levels of mouse apoC-III (Supplementary Figure 1A) [25, 26] . ApoC-III Tg mice also express the human transgene, as well as other apolipoprotein genes, in the colon (Supplementary Figure 1, A and B) . ApoC-III Tg mice are hyperlipidemic: plasma triglycerides are ~1,500 mg/dL and plasma cholesterol is ~300 mg/dL ( Supplementary Figure 1, C and D) . ApoC-III Tg mice have no obvious gut barrier disruption, as measured by plasma FITC-dextran after an oral gavage (Supplementary Figure 1E ). We exposed WT and apoC-III Tg mice to 4% DSS for 5 days followed by 5 days of water. ApoC-III Tg mice lost significantly less weight than WT controls (11.5% compared to 15.7% weight loss, respectively; ****P<0.0001) ( Figure 2A ). We found that apoC-III Tg mice were significantly protected from the physical symptoms of DSS including diarrhea, shivering, and lethargy compared to WT mice with a score of 0.7143 ± 0.1941 versus 4.571 ± 1.020, respectively ( Figure 2B ). ApoC-III Tg mice were resistant to colon shortening and thickening due to an accumulation of extracellular matrix, which is a well-established symptom of DSS-induced colitis ( Figure 2C ) [27] . ApoC-III Tg mice also showed significantly increased colon expression of the tight junction proteins occludin and zonulin-1 (ZO-1), strongly suggesting intact epithelial barrier function ( Figure 1D ) [28] .
After DSS treatment, apoC-III Tg and WT mice expressed comparable mRNA levels of TNF-α, IL-6, IFN-γ, and IL-10 in the colon ( Figure 1E ). TNF-α concentrations at baseline (untreated, chow-fed) did not differ between WT and apoC-III Tg mice (0.9307 pg/mL versus 1.397 pg/mL, respectively; data not shown), and both genotypes experienced a non-significant change in plasma TNF-α after DSS treatment ( Supplementary Figure 2A ). An important inflammatory mediator of colitis is IL-17, which works in opposition to Treg IL-10 [29] . The mRNA expression level of this cytokine was not different at baseline (data not shown) or after the DSS treatment period between WT and apoC-III Tg mice (Supplementary Figure 2B ). After DSS treatment, apoC-III Tg mice maintained significantly higher levels of circulating IL-10 ( Figure 2F ). Thus, apoC-III Tg mice showed resistance to DSSinduced colitis and maintained healthy intestinal barrier function.
The loss of IL-10-producing gut immune cells, such as CD103 + dendritic cells (DCs) and Tregs has been linked to symptoms of IBD [16] . We hypothesized that the resistance to DSS-induced colitis observed in apoC-III Tg mice was due to the accumulation of gut Tregs, which are potent sources of tolerogenic IL-10. We found that CD103 + DCs and mRNA expression of the Treg-related genes transforming growth factor (TGF)-β and FOXP3 are similar in the colon of both WT and apoC-III Tg mice ( Supplementary Figure 2 , C and D). Colonic LP Tregs in apoC-III Tg mice averaged 41,987 ± 22,137 cells versus 24,954 ± 15,949 in the colon of WT mice, although this difference was not significant ( Supplementary Fig. 2 , E and F). ApoC-III Tg mice also had similar colonic LP CD14 + monocytes compared to WT mice after DSS treatment (Supplementary Figure 2G ). ApoC-III Tg and WT mice had comparable CD103 + DCs in the mLN (Supplementary Figure 2H ), but apoC-III Tg mice had a significantly greater number of mLN-resident Tregs (*P=0.0124; Figure 2 , G and H). Thus, APOC3 overexpression results in an accumulation of Tregs and IL-10 in the gut and protects mice from DSS-induced colitis.
ApoC-III Tg mice accumulate intestine-homing Tregs.
Tregs in the gut, specifically the small intestinal and colonic LP and the gut-draining mLN, are potent sources of IL-10 [30] . We hypothesized that Treg accumulation in the gut of apoC-III Tg mice would also change the circulating cytokine profile. Plasma cytokine analysis between WT and apoC-III Tg mice showed no significant differences in circulating levels of tumor necrosis factor alpha TNFα, IL-6, IL-4, or interferon gamma (IFN-γ) ( Figure 3A ). However, apoC-III Tg mice had significantly higher concentrations of anti-inflammatory circulating IL-10 compared to WT mice (****P<0.0001; Figure 3B ). We found no significant differences in intracellular IL-10 in Tregs from the spleen or mLN in both genotypes ( Figure 3C ).
We found that apoC-III Tg mice also have an accumulation of splenic Tregs, compared to WT mice (****P<0.0001; Figure 3 , D and E). Tregs in apoC-III Tg spleen express C-C chemokine receptor type 9 (CCR9), which is activated by intestinal CCL25, an intestinal homing molecule ( Figure 3F ) [31] . This result suggests that splenic Tregs in apoC-III Tg mice might be homing to the intestine. We found no significant differences in mLN Treg populations or intestinal LP parent T cells (CD3 + or CD4 + Helper T cells) ( Figure 3 , G and H). In the intestinal LP, apoC-III Tg mice had a significant accumulation of Tregs compared to WT counterparts ( Figure 3 , I and J). This accumulation also occurred in the absence of changes to CD103 + DCs ( Figure 3K ).
We comprehensively analyzed the tissue compartments where apoC-III action is most potent (circulation and liver) to determine if excess apoC-III caused any other immune perturbations. We found no differences between WT and apoC-III Tg mice in the number of spleen-resident and circulating CD3 + T cells, CD4 + T cells, CD8α + T cells, or CD19 + B cells ( Supplementary Figure 3 , A-D). We also observed no difference in splenic or circulating CD14 + monocytes ( Supplementary  Figure 3 , E-H), despite previous reports showing that apoC-III-rich VLDLs can activate monocytes in vitro [32] . The liver, where apoC-III inhibits lipoprotein uptake, also had no differences in CD3 + T cells, CD4 + T cells, CD8α + T cells, and CD25 + T cells ( Supplementary Figure 4 ).
Because apoC-III Tg mice are hyperlipidemic (due to apoC-III inhibition of lipoprotein clearance from plasma to tissues) (Supplementary Figure 1C) , we used another model of hyperlipidemia to evaluate whether raising plasma lipids would recapitulate the intestinal Treg phenotype. We fed WT mice a 12-week Western diet. This high-fat, high-cholesterol diet resulted in increased total plasma cholesterol and triglycerides in WT mice versus chow-fed controls, mimicking basal apoC-III Tg plasma lipids (Supplementary Figure 5 , A and B). Flow cytometric analysis of the intestinal LP of Western diet-fed WT mice showed significant decreases in Treg populations compared to chow-fed controls (Supplementary Figure 5C ). This finding suggests that hyperlipidemia alone is not the cause of increased Treg populations in apoC-III Tg mice.
ApoC-III Tg Tregs are phenotypically comparable to WT Tregs.
We conducted an ex vivo analysis of WT and apoC-III Tg Tregs with and without T-cell receptor (TCR) stimulation to determine if there were phenotypic differences between these cells ( Figure 4 ). Under both conditions, we found no differences in the levels of the Treg cell surface markers CTLA-4, PD-1, GITR, LAG3, and NP-1 between the genotypes ( Figure 4A ). ApoC-III Tg Tregs express the APOC3 human transgene, but at a level 100 times less than liver expression of human APOC3 (Supplementary Figure 1F ). WT and apoC-III Tg Tregs have comparable expression levels of mouse APOC3 (Supplementary Figure 1F ). We stained Tregs with the cell cycle marker Ki-67 to identify which cells were actively proliferating [33] . Ki-67 staining was similar between WT and apoC-III Tg Tregs under both TCR-stimulated and unstimulated conditions ( Figure 4B ). To test whether isolated Tregs from WT and apoC-III Tg mice are different in their anergic state, we analyzed the amount of IL-2 in the cell culture media of isolated Tregs after 24 hours. Tregs are inherently anergic in vitro and require exogenous IL-2 to proliferate [34] . We found that both WT and apoC-III Tg Tregs are anergic and do not secrete any IL-2 ( Figure 4C , shown as ND). From this, we can conclude that there are no major phenotypic differences between WT and apoC-III Tg Tregs excluding expression of the human APOC3 transgene. This suggests that the change in Treg numbers in the intestine of apoC-III Tg mice is not due to a change in Treg activity or phenotype but is instead due to the accumulation of large numbers of Tregs in the gut.
A possible explanation for the increase in intestinal Tregs in apoC-III Tg mice is that the parent CD4 + T cells are proliferating in response to apoC-III inhibition of lipid uptake. We used Jurkat T cells to model parent CD4 + T cells. A significant advantage of Jurkat T cells is that we can avoid sorting T cells via fluorescence-activated cell sorting (FACS), which can change the intracellular metabolism of the cells [35] . We stained Jurkat T cells with Tag It Violet™ proliferation dye and treated them with human apoC-III-containing triglyceride-rich lipoproteins (TRLs) or apoC-III -/-TRLs. Jurkat T cells treated with hu-apoC-III-containing TRLs had a greater proliferation index compared to cells treated with apoC-III -/-TRLs (TRLs-apoC-III) ( Figure 4E ). These data suggest that apoC-III, by inhibiting lipid uptake from lipoproteins to T cells, results in the proliferation of parent T cells, which might account for the increasing size of the intestinal Treg pool. This demonstrates that the modulation of substrate delivery from lipoproteins to T cells could be a critical regulator of their proliferation and metabolism.
Tregs express lipid transporters, and apoC-III can inhibit their activity.
For an immune cell to use circulating TAG, the lipid must go through key physiological events, including endocytosis by LDLr and hydrolysis of the fatty acids. Whether T cells and Tregs acquire TAG from circulating lipoproteins, and whether this influences their activity is unknown. We first determined that Tregs express lipid transporters by mRNA analysis from isolated splenic Tregs (purity >80%) from WT and apoC-III Tg mice ( Figure 5A , Supplementary Figure 6 , A and B). To assess if there are tissue-specific expression differences in LDLr on Tregs, we analyzed multiple anatomical locations including the spleen, the gut-draining mLN and intestinal LP of WT mice ( Figure 5B ). As a percentage of the total Treg population, 98.5% of intestinal LP Tregs express LDLr. This is in contrast to splenic Tregs, where only 72.58% of Tregs express this receptor. When comparing between genotypes, we found that apoC-III Tg Tregs from the intestinal LP express the highest levels of LDLr ( Figure 5 , C and D). This suggests that LDLr may be a functional marker of gut Tregs.
As proof of principle, we first determined whether naïve T cells can endocytose TAG from lipoproteins and whether this is inhibited by apoC-III. Previous studies have used fatty acids bound to BSA or DMSO, or have addressed the impact of oxidized lipids from LDL and HDL on immune cells [36] [37] [38] . First, we confirmed the expression of LDLr in Jurkat T cells, our model for parent T cells, after treating them with TRLs containing varying amounts of apoC-III (Supplementary Figure  7) . LDLr expression in Jurkat T cells was similar between groups: no treatment (basal), treatment with TRLs from WT mice containing normal apoC-III levels, and treatment with TRLs containing excess apoC-III. Importantly, when treated with TRLs without apoC-III (no apoC-III) LDLr expression was downregulated which is a known regulatory step in liver in response to excess lipids [39] .
To determine whether apoC-III acts extrinsically on Jurkat T cells to inhibit lipid uptake, we treated cells with Bodipy-labeled TRLs with varying amounts of apoC-III. When treated with Bodipylabeled TRLs without apoC-III (TRLs-apoC-III), Jurkat T cells had the greatest lipid uptake compared to treatments with apoC-III ( Figure 5E , Supplementary Figure 8A and B). The addition of human apoC-III to Bodipy-labeled TRLs (TRLs+hu-apoC-III) inhibited lipid uptake compared to those with no apoC-III, resulting in significantly decreased lipid uptake into the cells ( Figure 5E ). Thus, apoC-III inhibits lipid uptake from TRLs into Jurkat T cells in a cell-extrinsic manner just as apoC-III inhibits TAG uptake in other tissues that express LDLr [4] .
In vivo inhibition of triglyceride transport shifts the metabolic program of apoC-III Tg Tregs.
Cellular metabolism is a key regulator of T cells and Tregs activity, including their proliferation at sites of inflammation, their differentiation to effector subsets, and their cytokine profile. We asked whether the inhibition TAG transport via LDLr had consequences for Treg metabolism, homeostasis, and activity in vivo. ApoC-III Tg Tregs have significantly increased expression of key lipolytic genes including hormone sensitive lipase (HSL) and patatin-like phospholipase domain (PNPL)-A2 (***P=0.0008), and key FAO genes including carnitine palmitoyltransferase (CPT)1-β and acyl-coenzyme A oxidase (ACOX)1(**P=0.0062; Figure 6A ). Concomitant with this increase in expression of lipolytic/oxidation genes, apoC-III Tg Tregs also showed decreased glucose transporter (GLUT1) mRNA compared to WT Tregs (**P=0.0070) ( Figure 6A ). This finding suggests a shift in apoC-III Tg Treg cellular metabolism from glycolysis and lipogenesis toward lipolysis and oxidative phosphorylation (OXPHOS). In contrast to apoC-III Tg Tregs, apoC-III -/-Tregs have decreased expression of HSL, which may suggest an alternative intracellular capacity for lipolysis ( Figure 6B ).
To confirm that this enzymatic capacity corresponded with a chance to in vivo metabolic flux, we used Seahorse analysis in splenic Tregs. We determined the oxygen consumption rate (OCR), which is a measure of OXPHOS, in isolated splenic Tregs from WT and apoC-III Tg mice (>80% purity) ( Figure 6C ). Although Tregs from apoC-III Tg and WT mice had similar responses to the ATP synthase inhibitor oligomycin and the proton gradient uncoupler FCCP, apoC-III Tg Tregs had an increased basal rate of OCR, confirming our gene expression analysis ( Figure 6D ). These data suggest that apoC-III Tg Tregs have increased basal respiration in response to excess apoC-III, and perhaps to the inhibited ability to take up lipid through LDLr. Although we show that Tregs upregulate lipolysis genes, it is unclear whether apoC-III Tg Tregs specifically break down intracellular TAG to fuel their increased basal respiration which is consistent with the mobilization of intracellular lipids in the absence of extracellular TAG transport.
LDLr -/mice are protected against DSS-induced colitis.
Since apoC-III's main action is to inhibit LDLr, we next asked whether LDLr -/mice would mirror colitis protection and recapitulate the tolerogenic phenotype seen in apoC-III Tg mice. To test this hypothesis, we treated LDLr -/and WT mice with DSS to induce colitis ( Figure 7 ). As predicted, the LDLr -/mice lost less body weight over the course of the treatment period (****P<0.0001; Figure  7A ). Although colon lengths were comparable, the LDLr -/mice had significantly lower macroscopic damage throughout the treatment period ( Figure 7 , B and C). LDLr -/mice showed significant increases in CD4 + T cells and Tregs themselves in the mLN after DSS treatment ( Figure 7 , D and E, Supplementary Figure 9A ). Although LDLr -/mice had increased numbers of CD14 + monocytes infiltrating the colonic LP, they had significantly greater amounts of Tregs (Figure 7 , F and G, Supplementary Figure 9B ). This suggests that gut tolerance occurs in LDLr -/mice as it does in apoC-III Tg mice during DSS treatment. Therefore, LDLr -/mice phenocopied the apoC-III Tg mice colitis protection after DSS treatment. This supports our hypothesis that lipid uptake via LDLr, and its inhibition when lipoproteins contain apoC-III, results in protection from DSS-induced colitis, and corresponds with an accumulation of gut and MLN Tregs. This is a previously unexplored pathway to stimulate intestinal immune tolerance.
Though there are alternative mechanisms for colitis protection in the face of the dramatic increase in gut Tregs (such as other cell types or activities), we find no evidence of this in either apoC-III Tg or LDLr -/mice. Given the significant increase in the number of Tregs that are accumulating in the apoC-III Tg intestine, and the fact that these are accompanied by a ~100-fold increase in IL-10, we do not find it surprising that apoC-III Tg mice are protected from colitis despite no change to Treg activity/proliferation/suppressive capacity. Though multiple cell types secrete IL-10, these cells are not increased in apoC-III Tg mice during chow diet, Western diet, or after DSS-colitis induction (data not shown, no statistical differences between WT and apoC-III Tg lymphoid and myeloid populations in plasma, spleen, thymus, liver). Identifying the cell responsible for elevated IL-10 in apoC-III Tg mice is a critical issue that has yet to be resolved.
Therapeutic treatment of apoC-III with chylomicrons protects from DSS-induced colitis.
Our data strongly suggest that TAG transport processes are involved in Treg homeostasis and colitis in mice. We therefore hypothesized that the inhibition of TAG transport, but not apoC-III protein in the absence of lipoprotein TAG, would stimulate Tregs and colitis protection in WT mice. We used the DSS model of colitis in WT mice receiving a daily intraperitoneal injection of one of three treatments: 1) PBS vehicle control, 2) purified human apoC-III, or 3) purified human apoC-III bound to WT triglyceride-rich lipoproteins. ApoC-III was provided at a concentration five times higher than physiological levels (55 mg/dL) to mimic conditions of apoC-III overexpression [40] . Injections were given intraperitoneally to ensure the treatments are cleared through the intestinal lymphatics before entering into circulation [41] . Over the course of the treatment period, WT mice given apoC-III on lipoproteins (apoC-III + TRLs) lost significantly less body weight compared to the group that received apoC-III alone (****P<0.0001) ( Figure 8A ). When comparing the qualitative macroscopic damage associated with DSS treatment, WT mice given apoC-III + TRLs had a lower macroscopic damage score compared to apoC-III alone ( Figure 8B ). Finally, after the treatment period, gene expression analysis of the colon of DSS-treated mice revealed a distinct Treg signature in mice give apoC-III + TRLs ( Figure 8C ). These mice had upregulated expression of FOXP3, the master transcription factor for the Treg lineage and IL-10. These findings suggest that apoC-III on lipoproteins may provide protection from DSS-induced colitis through the accumulation of intestinal Tregs and their IL-10.
Discussion
Using genetic and ex vivo models that inhibit LDLr and triglyceride transport from lipoproteins into immune cells, we show that apoC-III Tg and LDLr -/mice are both protected from DSS-colitis and simultaneously accumulate intestinal Tregs and IL-10. We show that T cells are capable of endocytosing TAG from lipoproteins, that this process is inhibited by apoC-III. This is the first evidence that Tregs and T cells use TAG, and that canonical regulators of TAG transport also regulate T cells and Tregs. We show that Tregs from apoC-III Tg are metabolically unique from WT Tregs and upregulate the genes of lipolysis and OXPHOS. Finally, we show that delivery of exogenous apoC-III on chylomicrons can protect WT mice from developing DSS-induced colitis.
A growing body of evidence suggests that Treg homeostasis relies on the ability to oxidize fatty acids. Tregs oxidize exogenous free fatty acids (palmitate), and the blockage of glycolysis, lack of exogenous glucose, or excess palmitate in the media will result in Treg enrichment, suppressive activity, and differentiation from CD4 + precursors[21, 22, 42, 43] . In addition, ex vivo Tregs will take up exogenous FFAs at a greater rate when they are rapidly proliferating, and during activation [37, 44] . Though these studies are critical to understanding how Tregs response to metabolic cues, they share the limitation that Tregs in vivo are normally exposed to triglyceride, not palmitate, in lipoproteins. We show for the first time that triglyceride-rich lipoproteins, the physiological lipid delivery system, can delivery Bodipy-TAG to T cells in culture, and that the loss of this pathway in vivo causes major changes to Treg accumulation, metabolism, and IL-10 concentrations in the gut. Physiologically, therefore, a key regulator of Treg function may be the presentation of triglyceride in lipoproteins.
Our data suggest that when Tregs are exposed to high levels of extracellular apoC-III on lipoproteins, those cells are deprived of exogenous lipid substrates. We find evidence for an intracellular switch in this condition, where ex vivo Tregs upregulate intracellular FAO but not glycolysis (via Seahorse and mRNA expression analyses). This finding is consistent with other studies that highlight Treg ability to switch from using TAG fuel to another other fuel sources which drive OXPHOS [38] . It will be important to determine how Tregs and T cells make up for the TAG they are unable to transport in the face of excess apoC-III. Prior to these findings, the role of extracellular triglyceride in immune cells was unknown.
Our study supports the findings by Rueda et al. that HDL internalization by Tregs promotes their survival and that blocking the oxidation of HDL lipids abolishes this effect [36] . Our studies add to this work by showing that lipoprotein triglyceride, and endocytosis, are critical for Tregs in models where LDLr is inhibited (both apoC-III Tg and LDLr -/mice). Further, this mechanism of triglyceride metabolism/lipoprotein triglyceride endocytosis may be unique to intestinal immune cells; we only find Treg accumulation in the gut of apoC-III Tg and LDLr -/mice. Further, by flow cytometry analyses of LDLr expression, Tregs can be stratified by their LDLr expression and their anatomical location, which Tregs in the gut expressing the highest LDLr. It is intriguing to speculate that the regulation by apoC-III might be unique to mLN Tregs, because these interact directly with intestinal lymph that carries diet-derived triglyceride and antigens on chylomicrons as well as intestinally-derived apoC-III. This would explain how apoC-III and LDLr can function as cardiovascular disease risk factors, where the thymic Treg responses predominate, and also act in an immunosuppressive manner in the gut [45] .
Both apoC-III Tg and LDLr -/mice are hyperlipidemic due to the inhibition of LDLr lipid uptake from plasma lipoproteins; therefore, we cannot fully dismiss a role for plasma hyperlipidemia in modulating tolerogenic gut T cells. However, the 12-week Western diet in WT mice which raised plasma triglyceride and cholesterol levels did not result in an accumulation of Tregs in the gut. This is consistent with several recent studies of plasma lipid metabolism and Treg biology. ApoE -/mice produce dysfunctional splenic CD4 + CD25 low Foxp3 + Tregs in response to a high fat diet [46] . In LDLr -/mice, Tregs accumulate in the liver and migrate to the aorta during hypercholesterolemia but do not confer protection from atherogenesis [47] . A key difference in apoC-III Tg mice, however, is that unlike apoE -/or LDLr -/mice, which have very high plasma cholesterol levels, apoC-III Tg mice have significantly higher plasma triglycerides (~1,500 mg/dL compared to ~200 mg/dL in LDLr -/and ~150mg/dL in apoE -/-). Hypercholesterolemia in LDLr -/mice results in expanded Treg populations, but impedes their suppressive capacity [45] . It is possible that the different plasma lipids (cholesterol versus triglycerides) have varying roles in Treg homeostasis; our data would suggest that lack of access to this lipid also modifies Treg populations.
Our studies have not established the mechanism by which excess apoC-III causes Treg accumulation in the intestine. We find no differences between WT and Treg markers, nor are there changes to the basal IL-2 secretion in apoC-III Tg Tregs. Intestinal Treg accumulation in apoC-III Tg mice could also be due to an increase in Treg homing to the gut, an increase in T cell differentiation, a decrease in conversion of Tregs to anergic ex-Tregs, or another mechanism that results in a change in total numbers of Tregs. Overall, we find that apoC-III overexpression in Tregs does not influence their proliferation, suppressive capacity, anergy, or surface marker phenotype. Ex vivo WT and apoC-III Tg Tregs behave similarly, with no differences in any of these measured with TCR stimulation. This suggests that our in vivo finding of increased Tregs in the intestine is not due to a change in Treg activity/phenotype but is instead due to the accumulation of large numbers of Tregs in the gut. Our data characterizing Tregs supports this conclusion.
We can exclude the possibility that the apoC-III Tg mice are mounting an immune response against the APOC3 transgene (thus resulting in the increase in intestinal Tregs) for multiple reasons. We do not observe any immune disease (intestinal or otherwise) in these mice, and they are immuno-competent since they do not succumb to any disease at a higher rate than their WT counterparts. They are able to mount a complete response to an intraperitoneal injection of lipopolysaccharide (data not shown). In addition, the highest expression of APOC3 is in liver, and we find no change to liver-resident immune cell populations ( Supplementary Figure 4) , despite the high level of transgene expressed there. We also carried out an initial histological characterization of apoC-III Tg intestine and found no differences in the gross intestinal anatomy of these mice (small and large intestinal mucosa, infiltrating macrophages, intestinal length, size and number of intestinal villi) (data not shown). Our analysis of total plasma and spleen immune cells shows no underlying inflammation or depletion of parent cells, and there is no leakiness in intestinal permeability in the apoC-III Tg mice (assessed via FITC-dextran challenge). Furthermore, baseline analysis of whole blood and spleen shows no difference in T cell populations and monocytes, except for Tregs, suggesting that it is unlikely that these mice are mounting an immune response towards apoC-III.
Our findings highlight a novel role of lipoproteins and LDLr inhibition in stimulating intestinal tolerance and colitis protection in mice. Whether there are other critical lipoprotein receptors and apolipoprotein regulation (like glycosylphosphatidylinositol-anchored HDL binding protein 1 (GPIHBP-1), LDLr-related protein 1 (LRP1), or LPL) seems likely. Our data challenge the concept that lowering plasma triglycerides by inhibiting or by lowering apoC-III levels is universally beneficial; these data suggest that clinically, APOC3 should be carefully considered in the context of both cardiovascular disease risk as well as IBD. Further, before treating patients with anti-apoC-III drugs, IBD risk may be an important clinical consideration. In short, for APOC3, what is good for the heart may not be good for the gut.
Methods
Animals.
Male and female C57BL/6J (WT) and human apoC-III transgenic (apoC-III Tg ) mice, both originating from heterozygous apoC-III Tg founders, were used for all studies (age 8-24 weeks). ApoC-III Tg mice were backcrossed six generations to C57Bl6/J mice. ApoC-III -/mice (Stock #002057, originally generated by Maeda, et al. [48] ) and LDLr -/mice (Stock # 002207, originally generated by Hammer and Herz, et al. [49] ) were purchased from The Jackson Laboratory (Bar Harbor, ME) and bred inhouse. A separate set of WT controls were bred from heterozygous founders of the apoC-III -/colony and WT mice (stock #000664) were purchased from The Jackson Laboratory to use as LDLr -/controls. ApoC-III Tg mice (founders generously provided by Dr. H. Dong, University of Pittsburgh) were originally generated by Dr. Jan Breslow [26] . All baseline measurements were taken from mice maintained on chow diet with no treatment.
All strains of mice were housed in the same facility, 2-5 animals per cage, in a temperaturecontrolled (25 ±1°C) vivarium on a 10-h light-dark cycle. Unless noted, mice had free access to water and chow diet (LM-485 Mouse/Rat Sterilizable Diet, Harlan Laboratories). For Western diet experiments, WT mice received Western diet (TD.88137, Harlan, Envigo), containing 42% kcal of butterfat and 0.2% of cholesterol, for 12 weeks ad libitum.
Blood measurements.
After an overnight fast, blood via tail clip was collected from mice to isolate plasma. Plasma triglycerides and cholesterol were determined by chemical assay (Randox #TR210 and #CH200, respectively, UK), according to manufacturer's protocol. For plasma cytokines, a terminal cardiac puncture was performed and whole blood was collected for serum isolation. Whole blood sat at room temperature for 20 minutes before centrifuging at 2,000 times gravity. Serum was isolated and frozen at -80°C until used for analysis. To determine IL-6, IL-10, IL-4, TNF-α, and IFN-γ levels, the EMD Millipore milliplex assay (catalog #MCYTOMAG-70k-05) was used according to the manufacturer's protocol; for IL-10 and TNF-α, a BioLegend IL-10 ELISA assay (catalog #431411) and TNF-α ELISA assay (catalog #430901, San Diego CA) were used, respectively, according to the manufacturer's protocol. For gut permeability analysis, mice were fasted for 6 hours and administered FITC-dextran (125 µg/µL, Sigma-Aldrich, St. Louis, MO) by oral gavage at 600 mg/kg body weight. After 1 hour, blood was collected for plasma analysis of FITC-dextran on a fluorescence spectrophotometer (BioTek Instruments, Inc., Winooski, VT) at excitation 485 nm and emission 535 nm. A standard curve was generated by diluting FITC-dextran in untreated mouse plasma.
Induction of colitis
Two weeks prior to all experiments, dirty cage bedding was swapped between apoC-III Tg , apoC-III -/-, and LDLr -/mice and their respective WT controls, to ensure identical environmental conditions [50] . Administration of 4-5% DSS (Colitis grade, M.W. 35 -50 kDa, MP Biomedicals) was given ad libitum in drinking water for 5 days, followed by fresh water for 5 days post-DSS treatment. Mice were assessed daily for body weight changes and macroscopic damage score [50] . Colitis symptoms were scored (0 = normal, 1 = mild, to 3 = severe) for symptoms of hunched posture, ruffled fur, rate of breathing, crusty eyes, shivering, diarrhea, rectal bleeding, rectal prolapse, activity upon handling, and body weight change. Mice with a score greater than 3 were sacrificed, and all mice were sacrificed at day 10. To calculate macroscopic damage score, the sum of the total scores for the 10-day period was averaged for each genotype.
ApoC-III treatment during colitis induction WT Mice were randomly assigned a daily treatment of phosphate-buffered saline, purified apoC-III, and purified apoC-III with WT TRLs (n=5 per group). Treatments were delivered via intraperitoneal injection at the same time, daily for the ten-day DSS treatment period. To mimic conditions in apoC-III Tg mice, purified human apoC-III (Academy Bio-Medical Company) were given at a dose that is five times greater than healthy, physiologic levels of apoC-III (55 mg/dL per dose per mouse) [40] . ApoC-III with WT TRLs will be delivered at the same concentration with TRLs at 200 mg/dL to mimic the post-prandial state. Injection volumes were maintained at 200 µL.
Tissue collection
Immediately following exsanguination using a terminal cardiac puncture, tissues were collected for flow cytometric or quantitative reverse transcription PCR (RT-qPCR) analysis. If collected for flow cytometry, tissue (MLNs, intestine, colon, spleen, and liver) was collected directly into phosphate buffered saline (PBS) and if collected for RT-qPCR (duodenum, ileum, colon, and liver) tissues were snap-frozen in liquid nitrogen and kept frozen at -80°C until RNA isolation. In addition, spleens were collected into PBS for Treg isolation.
Preparation of single-cell suspensions for flow cytometric analysis From the small intestine and the colon, the LP was isolated as previously described [51] . Briefly, small intestinal LP was isolated from the entire small intestine including duodenum through the ileum. The intestine and colon were incubated in predigestion buffer (HBSS with 5 mM EDTA and 1 mM DTT) for 30 minutes at 37°C, to remove epithelial cells, followed by two incubations in digestion buffer [collagenase Type 1 at 145 units/mL (Life Technologies) with DNase I at 25 units/µL (Invitrogen) in PBS], to break up connective tissue, releasing lymphoid cells. MLN, spleen, and liver were collected directly into PBS, and then tissue was mashed through a 70 µm strainer. MLN, spleen, and whole blood, which was collected via tail clip, were treated with erythrocyte lysis buffer (150 mM NH4Cl, 10 mM NaHCO3, 10 mM EDTA). All cells were pelleted and adjusted to 7-8 x10 6 cells/mL. Antibody staining for flow cytometric analysis Cells were stained with a live/dead discrimination dye (Zombie UV, catalog #423107, Biolegend). When appropriate, Fc receptors were blocked, using 10% FBS, before staining with anti-mouse fluorochrome-conjugated antibodies (Biolegend, see below for description). All antibody staining was conducted on ice, protected from light. Samples were fixed in 2% paraformaldehyde and permeabilized (1.6 mM Triton X-100 in PBS) for intracellular staining. For LDLr staining: cells were stained with primary LDLr antibody (Abcam, ab52818, 1:750), followed by secondary staining with Alexa 488 (Abcam, ab150065, 1:2,000). Cells were washed between each step using flow cytometry buffer (1x PBS, 5% FBS, 0.2 mM EDTA). Flow cytometry samples were run at the University of Connecticut Health Center Flow Cytometry Core. Samples were run using a BD LSR II (Becton-Dickinson Biosciences) after appropriate compensation. Collected events were set at 100,000.
Compensation controls using single stains were made using OneComp ebeads and UltraComp ebeads (Ebioscience) according to the manufacturer's instructions. Automatic compensation was conducted by FACS Diva software. Fluorescence minus one (FMO) controls were used to determine appropriate gate positions and FMO samples were created using the same tissue as the experimental sample, at the same time of experimental preparation.
Our gating strategy is summarized as follows. When gating any sample, leukocytes were identified by forward scatter (FSC)-area (FSC-A) by side scatter (SSC)-area, followed by identification of single cells using FSC-height by FSC-width. Finally, live cells were gated on using FSC-A by Live/Dead viability dye. Absence of the dye indicates live cells. Live cells were then identified as T cells using CD3 by FSC-A, and then further identified as helper T cells with CD4 by FSC-A. To distinguish Tregs, CD25 was gated by FOXP3 and double-positive cells were selected (CD25 + FOXP3 + ). FMO controls were used to determine all gates except FSC by SSC and single cells. 
Tag-It Violet™ proliferation analysis
For proliferation analysis, cells were stained with Tag-It Violet™ Proliferation and Cell Tracking Dye according to the manufacturer's instructions (Catalog #425101, Biolegend, San Diego, CA). Briefly, cells were stained for 12 minutes at 37°C with a 5 µM solution of Tag-It Violet™ in RPMI-1649 media without serum. Staining was quenched with five times the volume of RPMI-1640 with 10% FBS. Cells were then utilized for downstream applications. Proliferation analysis was conducted using FlowJo's Proliferation Tool (Treestar, Ashland, OR). Proliferation index is defined as the total number of divisions divided by the number of cells that went into division.
T-cell isolation and culture Tregs, defined CD4 + CD25 + , were isolated from the spleen and lymph nodes of WT, apoC-III Tg , and apoC-III -/mice using positive selection with MojoSort Streptavidin Beads (Catalog #480016, Biolegend) and Biotin-conjugated antibodies according to the manufacturer's instructions (anti-CD4, clone: GK1.5 and anti-CD25, clone: PC61). Briefly, single-cell suspensions from spleen were generated and cell concentrations were adjusted to 10 6 cells/mL in PBS. Samples were incubated for 20 minutes with 10 µL of CD4 + antibody followed by incubation with streptavidin-conjugated beads. MojoSort Magnet (BioLegend, catalog #480019) was used for two collections of the positive fraction and the collected CD4 + cells were used for the same staining and collection process with anti-CD25 antibody (for Tregs). To determine cell purity, an aliquot of cells was stained with an anti-CD4 (clone: Rm4-4) and anti-Foxp3 antibody. Cells had 80% purity or greater when gated on CD4 and Foxp3. Cell purity was determined using the gating strategy shown in Supplementary Figure 6A and FMOs for CD4 and Foxp3 are shown in Supplementary Figure 6B . Isolated cells were used for RNA isolation by freezing in Trizol or were plated in complete RPMI-1640 media for proliferation analysis or Seahorse Mito Stress Analysis. When cultured, purified IL-2 (25 U/mL), anti-CD3 (0.5 µg/mL), and anti-CD28 (1 µg/mL) (Biolegend, catalog #504701, 100201, and 102101) were added to maintain a CD4 + CD25 + Treg population. WT CD4 + CD25 + Tregs cultured for proliferation analysis were treated with TRLs from apoC-III -/-, WT, and apoC-III Tg mice for 96 hours. Plasma was standardized by triglyceride content after a triglyceride assay.
Ex vivo Treg analysis CD4 + CD25 + cells were isolated using negative selection of CD4 + T cells using the MojoSort Mouse CD4 Naïve T-cell Isolation Kit (catalog #480040, Biolegend) followed by positive selection of CD25 + , as described above. Isolated cells were cultured in complete media with and without TCR stimulation. For TCR stimulation, anti-CD3 (0.5 µg/mL) and anti-CD28 (1 µg/mL) were added to complete RPMI media. After 24 hours, cells were collected and stained with following phenotyping markers: Brilliant Violet CD152/CTLA-4 (Clone: UC10-4B9), PE CD223/LAG3 (Clone: C9B7W), PE/Cy7 CD357/GITR (Clone: YGITR765), PerCP/Cy5.5 CD279/PD-1 (Clone: 29F.1A12), APC CD304/Neuropilin-1 (Clone: 3E12), and Alexa Fluor 594 Ki67 (Clone: 11F6). Cell culture supernatant was collected and frozen for IL-2 analysis using LEGENDplexä technology according to the manufacturer's instructions (Biolegend).
Isolation of triglyceride-rich lipoproteins
After a four-hour fast, WT and apoC-III -/mice were gavaged with Bodipy FL C12 (D3822, Life Technologies, Eugene, OR) at 2 µg/g body weight dissolved in olive oil or olive oil alone at a final volume of 200 µL. Three-four hours post-gavage, blood was collected via cardiac puncture and allowed to coagulate at room temperature. Serum was isolated via centrifugation at 2,000 x gravity for 20 minutes. Serum was transferred to a 4.7 mL ultracentrifuge tube and overlaid with 300 µL saline. Samples were spun at 50,000 rpm in a TLA110 rotor using the Optima Max-TL Ultracentrifuge (Beckman Coulter) for over 12 hours, and the top fraction was collected for use. Samples containing Bodipy were protected from light throughout preparation. Isolated TRLs were used in Jurkat T-cell experiments, cell proliferation analyses, and Seahorse analyses.
Jurkat T-cell cultures
Jurkat T-cells (clone E6-1, ATCC TIB-152, Manassas, VA) were grown in RPMI-1640, supplemented with 10% FBS and 1% penicillin/streptomycin in an atmosphere of 5% CO2 at 37°C. When treated with TRLs, cells were serum-starved overnight then administered TRLs with and without purified human apoC-III at 20 µg/mL (Academy Bio-Medical Co, Houston, Texas). For lipid uptake experiments, cells were treated for 48 hours, and then collected for flow cytometric analysis. For proliferation analysis, cells were stained with Tag-It Violet Proliferation dye (catalog #425101, Biolegend), treated for 96 hours, and then collected for flow cytometric analysis. For RNA analysis, cells were collected in Trizol.
Seahorse XF Cell Mito stress analysis
The OCR was measured with an XFp analyzer (Agilent Technologies, Santa Clara, CA). Cultured primary CD4 + CD25 + Tregs were isolated and cultured as described above. Isolated cells were incubated for 12-16 hours in RPMI-1640 media, and then cells were seeded at a density of >200,000 cells per well of an XFp cell culture microplate. Before assay, cells were equilibrated for 1 h in unbuffered XF assay medium supplemented with 1 mM pyruvate, 2mM glutamine and 10 mM glucose. Mixing, waiting, and measure times were 2, 2, and 4 min, respectively. Compounds were injected during the assay at the following final concentrations: 7.5 µM oligomycin and 7.5 µM FCCP, for OCR measurements.
qRT-PCR Snap-frozen organ fragments were mechanically homogenized with the use of a Tissue Tearor (Biospec Products, LLC). Total RNA was extracted from homogenized tissue and isolated cells using Tri-Reagent (LifeTechnologies) according to the manufacturer's instructions. cDNA was synthesized using a Reverse Transcriptase kit (Promega). Quantitative real-time PCR was conducted using primer sets in Supplementary Table 1 and mRNA levels were analyzed in duplicate using SYBR green (Invitrogen) using a thermocycler (BioRad CFX Connect Real Time System). Samples were normalized to cyclophilin. For fold change, samples were then standardized to WT averages.
Statistics
Statistical analyses were performed using GraphPad Prism software, version 6. All results are expressed as mean ± SEM. Results were analyzed by Student's t test (unpaired with equal standard deviations), comparing genotypes or treatments, after a test to identify outliers was conducted (ROUT outliers, Q=1%) or using a two-way ANOVA with Sidak's post-hoc analysis after outliers were identified. Differences with a P value of less than 0.05 were considered statistically significant (*P<0.05, **P<0.01, ***P<0.0001, ****P<0.00001).
Data Availability
The data that support the findings in this study are available from the corresponding author upon request. Supplementary Table 1 : mRNA primers for RT-qPCR analysis. 
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